ArticleOncogene2000
Regulation of mda-7 gene expression during human melanoma differentiation.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 54 citations in OpenAlex.
- The investigation of the death-inducing potency of a recombinant Adenovector expressing Mda-7-tlyp-1 on different cancer cell lines.Gastroenterology and hepatology from bed to bench · 2024Article
- Enhancement of recombinant human IL-24 (rhIL-24) protein production from site-specific integrated engineered CHO cells by sodium butyrate treatment.Bioprocess and biosystems engineering · 2022Article
- Insights into the Mechanisms of Action of MDA-7/IL-24: A Ubiquitous Cancer-Suppressing Protein.International journal of molecular sciences · 2021Review
- An Oncolytic Vaccinia Virus Armed with GM-CSF and IL-24 Double Genes for Cancer Targeted Therapy.OncoTargets and therapy · 2020Article
- Therapy of prostate cancer using a novel cancer terminator virus and a small molecule BH-3 mimetic.Oncotarget · 2015Article
- Article
- MDA-7/IL-24: multifunctional cancer killing cytokine.Advances in experimental medicine and biology · 2014Review
- Molecular targets and signaling pathways regulated by interleukin (IL)-24 in mediating its antitumor activities.Journal of molecular signaling · 2013Article
- Molecular Mechanisms Governing IL-24 Gene Expression.Immune network · 2012Article
- mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity.Cytokine & growth factor reviews · 2010Review
- HDAC4 inhibits the transcriptional activation of mda-7/IL-24 induced by Sp1.Cellular & molecular immunology · 2010Article
- The p38 MAPK regulates IL-24 expression by stabilization of the 3' UTR of IL-24 mRNA.PloS one · 2010Article
- IL-24: a classic cytokine and/or a potential cure for cancer?Journal of cellular and molecular medicine · 2008Review
- Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine.Pharmacology & therapeutics · 2006Review
- The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells.Oncogene · 2002Article
- Article
- ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins.Nucleic acids research · 2001Article
- Interleukin-24: A Multidimensional Therapeutic for Treatment of Human Diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Induction of irreversible growth arrest and terminal differentiation in human melanoma cells following treatment with recombinant human fibroblast interferon (IFN-beta) and mezerein (MEZ) results in elevated expression of a specific melanoma differentiation associated gene, mda-7. Experiments were conducted to define the mechanism involved in the regulation of mda-7 expression in differentiating human melanoma cells. The mda-7 gene is actively transcribed in uninduced HO-1 human melanoma cells and the rate of transcription of mda-7 is not significantly enhanced by treatment with IFN-beta, MEZ or IFN-beta+MEZ. The high basal activity of the mda-7 promoter in uninduced melanoma cells and the absence of enhancing effect upon treatment with differentiation inducers is corroborated by transfection studies using the promoter region of mda-7 linked to a luciferase reporter gene containing the SV40 polyadenylation signal sequence. RT - PCR analysis detects the presence of low levels of mda-7 transcripts in uninduced and concomitant increases in differentiation inducer treated HO-1 cells. However, steady-state mda-7 mRNA is detected only in IFN-beta+MEZ and to a lesser degree in MEZ treated cells. We show that induction of terminal differentiation of HO-1 cells with IFN-beta+MEZ dramatically increases the half-life of mda-7 mRNA while treatment with cycloheximide results in detectable mda-7 mRNA in control and inducer treated cells. These observations confirm constitutive activity of the mda-7 promoter in HO-1 cells irrespective of differentiation status suggesting posttranscriptional processes as important determinants of mda-7 expression during terminal differentiation. The 3' UTR region of mda-7 contains AU-rich elements (ARE) that contribute to rapid mda-7 mRNA turnover during proliferation and reversible differentiation, a process controlled by a labile protein factor(s). Substitution of the SV40 polyadenylation signal sequence in the luciferase reporter plasmid with the mda-7-ARE-3'-UTR renders the Luciferase message unstable when expressed in proliferating and reversibly differentiated melanoma cells. In contrast, the luciferase message is stabilized when the mda-7-ARE-3'-UTR construct is expressed in terminally differentiated HO-1 cells. These results provide compelling evidence that mda-7 expression during terminal differentiation in human melanoma cells is regulated predominantly at a posttranscriptional level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.